CSL Limited: Primary Immunodeficiency Diseases trials

The registry lists 17 Primary Immunodeficiency Diseases studies with CSL Limited as lead sponsor. 0 are open to participants now and 8 have results posted.

Phase 3 12Phase 4 4No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID)CompletedNCT03033745Phase 4Results posted
• Follow-up Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan Study)CompletedNCT01458171Phase 3Results posted
• Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan Study)CompletedNCT01199705Phase 3Results posted
• Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (EU Extension Study)CompletedNCT00751621Phase 3Results posted
• Extension Study of Subcutaneous Immunoglobulin Human in Patients With Primary Immunodeficiency (PID)CompletedNCT00719680Phase 3Results posted
• Efficacy and Safety of Vivaglobin® in Previously Untreated Patients With Primary ImmunodeficiencyCompletedNCT00520494Phase 4Results posted
• Study of Subcutaneous Immunoglobulin in Patients With PID Requiring IgG Replacement TherapyCompletedNCT00419341Phase 3Results posted
• Safety and Efficacy of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)CompletedNCT00322556Phase 3Results posted
• An Open-label, Multicenter Study to Assess the Pharmacokinetics (PK), Safety, and Tolerability of Subcutaneous IgPro20 in Immunoglobulin (IG) Treatment-naïve Participants With Primary Immunodeficiency (PID)CompletedNCT07076446Phase 4
• Study of Immune Deficiency Patients Treated With Subcutaneous Immunoglobulin (IgPro20, Hizentra®) on Weekly and Biweekly SchedulesCompletedNCT02711228Phase 4
• Multicenter Study of Long-Term Clinical Outcomes of Subcutaneous Immune Globulin IgPro20 in Subjects With Primary Immunodeficiency (Japan Study)CompletedNCT01461018Phase 3
• Retrospective Chart Review of Subcutaneous IgG Use in InfantsCompletedNCT01166074
• Safety Study of Subcutaneous Ig NextGen 16% in Patients With Primary ImmunodeficiencyCompletedNCT00680446Phase 3
• Ig NextGen 10% in Patients With Primary Immune Deficiency (PID)CompletedNCT00405184Phase 3
• Subcutaneous Ig NextGen 16% in PID PatientsCompletedNCT00391131Phase 3
• Efficacy and Safety of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)CompletedNCT00168025Phase 3
• Efficacy and Safety of Intravenous Immunoglobulin IVIG-F10 in Patients With Primary Immunodeficiencies (PID)CompletedNCT00168012Phase 3